Mirtazapina Mylan (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Mylan, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapina Mylan is a NaSSA antidepressant that modulates norepinephrine and serotonin pathways to improve mood in depressive conditions. - Major depressive disorder: reduces depressive symptoms and improves functional capacity. - Depressive episodes with insomnia: promotes sleep onset and continuity. - Depressive episodes with anxiety: alleviates anxiety components associated with depression.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness or sedation. - Increased appetite and weight gain. - Dry mouth. - Constipation. - Dizziness. - Peripheral edema.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Seizures. - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome). - Hepatic dysfunction. - Suicidal thoughts, especially early in treatment. - Orthostatic hypotension.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown excretion; consider alternatives. - Elderly: start at low dose and monitor for excessive sedation. - Hepatic or renal impairment: dose adjustment may be required. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Mirtazapine can affect or be affected by several concomitant medicines.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): possible altered metabolism. - Anticholinergic agents: may exacerbate dry mouth and constipation. - Warfarin: monitor INR for potential changes.